Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome

Blood

Volumn 90, Issue 5, 1997, Pages 1737-1746

  Baiocchi, Robert A ^b   Khatri, Vijay P ^b   Lindemann, Matthew J ^b   Ross, Mary E ^b   Papoff, Giuliana ^b   Caprio, Anthony J ^b   Caprio, Thomas V ^b   Fenstermaker, Robert ^b   Ruberti, Giovina ^b   Bernstein, Zale P ^b   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; INFECTION RISK; LYMPHOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030954680     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.1737     Document Type: Article

References (44)

1. Peters BS, Beck EJ, Coleman DG, Wadsworth MJ, McGuinness O, Harris JR, Pinching AJ: Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. Br J Haematol 302:203, 1991
2. Miller G: Epstein-Barr virus. Biology, pathogenesis and medical aspects., in Fields B, Knipe (ed): Field's Virology (ed Second). New York, NY, Raven, 1990, p 1921
3. Meeker TC, Shiramizu B, Kaplan L, Herndier B, Sanchez H, Grimaldi JC, Baumgartner J, Rachlin J, Feigal E, Rosenblum M, et al: Evidence for molecular subtypes of HIV-associated lymphoma: Division into peripheral monoclonal, polyclonal and central nervous system lymphoma. AIDS 5:669, 1991
4. Levine AM, Shibata D, Sullivan-Halley J, Nathwani B, Brynes R, Slovak M, Bauch S, Riley L, Weiss L, Levine P, Rasheed S, Bernstein L: Case control study of HIV-positive and HIV-negative lymphoma in Los Angeles County. Proc Am Soc Clin Oncol 11:333, 1992
5. MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969, 1991
6. Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N, Monforte AD, Wahren B, Lazzarin A, Linde A: Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 342:398, 1993
7. Beral V, Pertman T, Berkelman R, Jaffe H: AIDS associated non-Hodgkins lymphoma. Lancet 337:805, 1991
8. Shibata D, Weiss LM, Hernandez AM, Nathwani BN, Bernstein L, Levine AM: Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 81:2102, 1993
9. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78:539, 1994
10. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71, 1995
11. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747, 1989
12. Debatin K-M, Goldmann CK, Bamford R, Waldmann TA, Krammer PH: Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 335:497, 1990
13. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, Akagi T: Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 145:330, 1994
14. Falk MH, Trauth BC, Debatin K-M, Klas C, Gregory CD, Rickinson AB, Calender A, Lenoir BM, Ellwarrt JW, Krammer PH, Bornkamm GW: Expression of the Apo-1 antigen in Burkitt lymphomas cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 79:3300, 1992
15. Rowe M, Rowe DT, Gregory CD, Young LS, Farrel PJ, Rupani H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO 6:2743, 1987
16. Camilleri-Broet S, Feuillar DJ, Bourgeois C, Seeilhean D, Hauw J, Raphael M: High expression of latent membrane protien 1 of Epstein-Barr virus and BCL-2 oncoprotien in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 85:432, 1995
17. Bashir R, Luka J, Cheloha BS, Chamberlain M, Hochberg A: Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology 43:2358, 1993
18. Kamel-Reid S, Dick JE: Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 242:1706, 1988
19. Mosier DE, Gulizia RJ, Baird SM, Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335:256, 1988
20. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB: Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173:147, 1991
21. Purtilo DT, Falk F, Pirrucello SJ, Nakamine H, Kleveland K, Davis JR, Okano M, Taguki Y, Sanger WG, Beisel KW: Seid mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. Int J Cancer 47:510, 1991
22. Bosma GC, Fried M, Custer RP, Carroll A, Gibson DM, Bosma MJ: Evidence of functional lymphocytes in some (leaky) scid mice. J Exp Med 167:1016, 1988
23. Matos ME, Schnier GS, Beecher MS, Ashman LK, Williams DE, Caligiuri MA: Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 178:1079, 1993
24. Alderson MR, Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley K, Miller RE, Lynch DH: Regulation of apoptosis in T cell activation by Fas-specific monoclonal antibodies. Int Immunol 6:1799, 1994
25. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar J, Croce CM, Caligiuri MA: Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 85:1063, 1995
26. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G: An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 156:4622, 1996
27. Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706, 1995
28. Cascino I, Papoff R, De Maria R, Testi R, and Ruberti G: Fas/ Apo-1/CD95 receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156:1317, 1996
29. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759, 1994
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271, 1991
31. Rieus-Laucat F, LeDeist F, Hivroz C, Roberts AG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347, 1995
32. Hong J-H, Gatti RA, Huo YK, Chiang C-S, McBride WH: G2/M-Phase arrest and release in ataxia telangiectasia and normal cells after exposure to ionizing radiation. Rad Res 140:17, 1994
33. Mitsuyasu RT, Lee F-C, Cooper JS: AIDS-related malignancies, in Pazdur R, Coia LR, Hoskins WJ, Wagman LD (ed): Cancer Management: A Multidisciplinary Approach, (ed 1). Huntington, NY, PRR, Inc, 1996, p 528
34. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S: Cross-linking of CD4 molecules upregulates FAS antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis facor-α secretion. Blood 84:2622, 1994
35. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
36. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107, 1991
37. Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteu A, Henrion A, Bouscary D, Varlet P, Joulin V, Kahn A: Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 2:80, 1996
38. Ogasawara J, Watanabe-Fukunag R, Adachi M, Matsuzawa A, Kasugai T, Kitamuria Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364:806, 1993
39. Arase H, Arase N, Saito T: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181:1235, 1995
40. Leithauser F, Dhein J, Gunhild M, Koretz K, Bruderlien S, Henne C, Schmidt A, Debatin KM, Krammer P, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
41. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA: Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86:3287, 1995
42. Rouquet N, Pages JC, Molina T, Briand P, Joulin V: ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr Biol 6:1192, 1996
43. Bashir R, Okano M, Kleveland KM, Pirrucello S, Masih A, Sanger W, Fordyce-Boyer R, Purtillo D: SCID/human mouse model of central nervous system lymphoproliferative disease. Lab Invest 65:702, 1991
44. Itoh N, Yonohara S, Ishil A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66:233, 1991